George Siber

From Wikipedia, the free encyclopedia
George R. Siber
George Siber 2014.png
Born(1944-09-07)September 7, 1944
Bavaria
CitizenshipCanadian and American (dual)
Alma materMcGill University
Spouse(s)
Angelia Siber
​
(m. 2006)​
Scientific career
FieldsVaccinology
Doctoral advisor and [1]
InfluencesJohn Franklin Enders,[2] ,[3] ,[4] John Robbins, Robert Austrian, Maurice Hilleman

George Rainer Siber (born September 7, 1944) is a medical researcher and vaccine expert with 46 years of experience in developing numerous vaccines, therapeutic antibodies, and diagnostic agents for infectious diseases.

Siber is a former Harvard professor, current adjunct professor at Johns Hopkins University and professor at the University of Massachusetts Medical School, former executive vice president and chief science officer of Wyeth, and advisory committee member of the World Health Organization, US National Institutes of Health, Gates Foundation, and the National Institute of Allergy and Infectious Diseases.[5][6]

Biography[]

Early life and education[]

Siber emigrated from Bavaria, Germany, with his parents at age nine in 1953 to Montreal. At the time, he spoke no English. Later, he attended Chambly Academy, where he graduated in 1962. It was at Chambly, which later become Penfield Academy, that Siber was convinced by Wilder Penfield to pursue a career in medicine.[7]

After high school, he attended Bishop's University in Lennoxville, Quebec from 1962 to 1966, where he graduated with honors and obtained a Bachelor of Science. Siber then attended McGill University in Montreal, Quebec, Canada, where he became a Doctor of Medicine in 1970. It was during this time that Siber published research he completed at the Montreal Neurological Institute.[8]

Siber is both a US and Canadian citizen. He has homes in Manhattan and Beijing.

Interships, residencies, and fellowships[]

After graduation in 1970, Siber held several internships, residencies, and fellowships. Between 1970 and 1972, Siber worked in Chicago as an intern and junior medical resident at Rush University Medical Center. In 1972, Siber moved to Boston and worked as a senior medical resident and clinical fellow in medicine at Beth Israel Hospital until 1973. Between 1973 and 1975, Siber worked as a clinical fellow in infectious diseases and research fellow in medicine at Beth Israel Hospital, Boston Children's Hospital, and Harvard Medical School. Between 1974 and 1975, Siber was also a fellow for the Medical Research Council of Canada.[9]

Professional experience[]

Industry appointments[]

Siber has held several industry appointments for various companies since the mid-1990s.

Siber served as the vice president, chief scientific officer, and senior vice president, and executive vice president for Wyeth from 1996 to 2006.[9]

Siber oversaw the development and approval of several vaccines for Wyeth: including Prevnar pneumococcal vaccine; acellular pertussis vaccine; meningococcal meningitis vaccine; Rotashield rotavirus vaccine; and, FluMist influenza vaccine.[10][11]

Since retiring from Wyeth Siber has served on the boards of directors of several companies, Since 2007, Siber has served as the executive chairman (until 2013) and as executive director and chairman of the scientific advisory board for in Cambridge, Massachusetts. In 2009 he was appointed as the director of in Watertown, Massachusetts. In 2012 he joined the board of directors and SAB of and the board of , also known as (SABC), in Luoyang, China. In 2014 he co-founded and serves on the board of directors.[9][12][13][14][15][16]

Siber joined ClearPath Vaccine Company in 2012 and became its chief scientific officer in 2013.[9]

Siber was appointed to the board of trustees of the International Vaccine Institute in Korea in 2014 and chairs the board's science committee.[17][18]

Siber has served on numerous scientific advisory committees, including Variation Biotechnologies in Cambridge (2008–09), in (2008–12), Medford, Massachusetts (2008–12), (previously Neotope) in San Francisco (2009–present), in Cambridge (2011–14), in Boston (2013–present), Vaxess in Cambridge (2014 – present) in San Diego (2014–present), and (2014–present). Siber also serves on the external advisory board of Aditec on behalf of the EC (2009–present), the Korean FDA, (2011–present) and the Vaccine Advisory Committee of the Wistar Institute in Philadelphia (2012–present).

Department of Public Health appointments[]

Siber served as the assistant director and head of bacterial vaccines for the in Jamaica Plain, Massachusetts, between 1982 and 1983. In 1983, he was promoted to the position of director, where he served until 1996.

Academic appointments[]

Since 1975, Siber has held several academic appointments and teaching positions.

Siber has held positions at Harvard Medical School (associate professor until 1996), Tufts University School of Medicine, University of Massachusetts Medical School (professor of medicine until 2012), and the Johns Hopkins Bloomberg School of Public Health (adjunct professor from 2008 to present).[9][19]

Between 1975 ad 1996, Siber held several hospital appointments at various hospitals, including Beth Israel Hospital, the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Newton-Wellesley Hospital, , Harvard University Health Services, and the Children's Hospital. He served as an assistant physician, associate in medicine, and as courtesy staff across those locations.[9]

Products developed and licenses for marketing and sale[]

Siber has been directly involved in the creation of several products, most of which were created while working for Wyeth and Mass Biologics.

Siber holds patents on , a diagnostic kit for bacterial meningitis, , the first Human respiratory syncytial virus immune globulin, and Prevnar, the first Pneumococcal Pneumonia Conjugate.[18]

Respigam was the first antibody licensed for preventing severe RSV infections in high-risk infants and was the precursor product to Synagis, the first human monoclonal antibody for infectious diseases. Prevnar 7 and 13 are for the prevention of pneumococcal infections, the most common and severe bacterial infection of children and elderly adults worldwide causing mortality exceeding 1 million per year. Prevnar is also the most successful commercial vaccine of all time with sales exceeding four billion dollars per year.

Siber also developed , the first , , the first infant botulism immune globulin, the Haemophilus influenzae conjugate vaccine in licensed to Berna, , an , , the first , Rotashield, the first Rotavirus diarrhea vaccine, and FluMist, the first Live attenuated influenza vaccine.[9][17][18][20]

Siber became a diplomate with the National Board of Medical Examiners in 1971, a diplomate with the American Board of Internal Medicine in 1973, and a diplomate in infectious diseases for the American Board of Internal Medicine.

Awards[]

  • 1962-1966 – Domtar Scholar, Bishop's University, Lennoxville, Quebec, Canada
  • 1966-1970 – University Scholar, McGill University, Montreal, Quebec, Canada
  • 1968–present – Alpha Omega Alpha
  • 1970 – Holmes Gold Medal, McGill University, Montreal, Quebec, Canada
  • 1970 – J. Francis Williams Scholarship in Clinical Medicine, McGill University, Montreal, Quebec, Canada
  • 1971 – Rush Medical College Award, Rush-Presbyterian-St. Luke's Hospital, Chicago, Illinois (Best Medical Intern)
  • 1972 – Department of Medicine Award, Rush-Presbyterian-St. Luke's Hospital, Chicago, Illinois (Best Medical Resident)
  • 1975 – Canadian MRC Fellowship in Infectious Diseases
  • 2008 – Dedication of Massachusetts Biologic Laboratories Research and Development Building, Mattapan, MA to George R. Siber and Jeanne Leszczynsky
  • 2016 – Albert B. Sabin Gold Medal

References[]

  1. ^ "Vaccine Technology Takes Center Stage in Rochester". University of Rochester Medical Center. 1998-10-08. Retrieved 7 July 2014.
  2. ^ "Part of Team that Created Remarkable Hib Vaccine". Science Heroes. Retrieved 7 July 2014.
  3. ^ Pearson, David (Spring 2011). "The Problem Solver". . Retrieved 7 July 2014.
  4. ^ "Albert Lasker Clinical Medical Research Award – 1996". Lasker Foundation. Archived from the original on 16 January 2014. Retrieved 8 July 2014.
  5. ^ "ClearPath Development Team". ClearPath Development Company. Retrieved 7 July 2014.
  6. ^ Clark, Thornton. "Porter Anderson". The Encyclopedia of Alabama. Retrieved 7 July 2014.
  7. ^ "Chambly County High School & Chambly Academy Alumni Association". Chambly County. Archived from the original on 3 September 2014. Retrieved 2 April 2014.
  8. ^ Sherwin, A.L.; Siber, G.R.; Elhilali, M.M. (August 1967). "Fluorescence technique to demonstrate creatine phosphokinase isozymes". Clinica Chimica Acta. 17 (2): 245–249. doi:10.1016/0009-8981(67)90127-1. PMID 4382430.
  9. ^ Jump up to: a b c d e f g "14th Annual World Vaccine Congress 2014". . Retrieved 21 March 2014.
  10. ^ "Astellas To Form Strategic Partnership With Clearpath To Build Vaccine Portfolio-In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics-". Astellas. 2014-01-06. Retrieved 2 April 2014.
  11. ^ "Genocea Biosciences Appoints Katrine Bosley As Chairman Of The Board Of Directors; Vaccine Industry Leader George Siber, M.D. To Serve As Executive Director And Head Of Scientific Advisory Board". BizJournals. 2013-11-18. Retrieved 24 March 2014.
  12. ^ Crawford, Steve (2010-10-28). "Dr. George Siber Joins Ancora Pharmaceuticals Scientific". Bloomberg. Retrieved 20 March 2014.
  13. ^ "Selecta Board of Directors". . Archived from the original on 7 December 2013. Retrieved 24 March 2014.
  14. ^ "External Advisory Board – Dr George Siber". . Retrieved 20 March 2014.
  15. ^ "Vaccine Industry Leader George Siber, M.D. Joins Vaxess Technologies As Chairman Of Scientific Advisory Board" (PDF). Vaxess Technologies. Archived from the original (PDF) on 23 February 2014. Retrieved 20 March 2014.
  16. ^ "Prothena Scientific Advisory Board". . Archived from the original on 9 March 2014. Retrieved 24 March 2014.
  17. ^ Jump up to: a b "Scientific Team". . Archived from the original on 10 September 2014. Retrieved 9 July 2014.
  18. ^ Jump up to: a b c "Genocea Prospectus". NASDAQ. Retrieved 9 July 2014.
  19. ^ "George Siber, MDCM". Johns Hopkins Bloomberg School of Public Health. Archived from the original on 11 September 2014. Retrieved 24 March 2014.
  20. ^ "Genocea Biosciences Inc (GNCA:NASDAQ GM)". BusinessWeek. 07/08/2014. Retrieved 9 July 2014. Check date values in: |date= (help)

Bibliography[]

Journals[]

  • Simoes, EA; Groothuis, JR; Tristram, DA; Allessi, K; Lehr, MV; Siber, GR; Welliver, RC (Aug 1996). "Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children". The Journal of Pediatrics. 129 (2): 214–9. doi:10.1016/s0022-3476(96)70245-7. PMID 8765618.
  • Shahid, NS; Steinhoff, MC; Hoque, SS; Begum, T; Thompson, C; Siber, GR (Nov 11, 1995). "Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine". Lancet. 346 (8985): 1252–7. doi:10.1016/s0140-6736(95)91861-2. PMID 7475716. S2CID 25681573.
  • Englund, JA; Glezen, WP; Thompson, C; Anwaruddin, R; Turner, CS; Siber, GR (Dec 1997). "Haemophilus influenzae type b-specific antibody in infants after maternal immunization". The Pediatric Infectious Disease Journal. 16 (12): 1122–30. doi:10.1097/00006454-199712000-00005. PMID 9427456.
  • Black, S; Shinefield, H; Fireman, B; Lewis, E; Ray, P; Hansen, JR; Elvin, L; Ensor, KM; Hackell, J; Siber, G; Malinoski, F; Madore, D; Chang, I; Kohberger, R; Watson, W; Austrian, R; Edwards, K (Mar 2000). "Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group". The Pediatric Infectious Disease Journal. 19 (3): 187–95. doi:10.1097/00006454-200003000-00003. PMID 10749457. S2CID 72133749.
  • Hausdorff, WP; Bryant, J; Paradiso, PR; Siber, GR (Jan 2000). "Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I." Clinical Infectious Diseases. 30 (1): 100–21. doi:10.1086/313608. PMID 10619740.
  • Eskola, J; Kilpi, T; Palmu, A; Jokinen, J; Haapakoski, J; Herva, E; Takala, A; Käyhty, H; Karma, P; Kohberger, R; Siber, G; Mäkelä, PH; Finnish Otitis Media Study Group (Feb 8, 2001). "Efficacy of a pneumococcal conjugate vaccine against acute otitis media". The New England Journal of Medicine. 344 (6): 403–9. doi:10.1056/nejm200102083440602. PMID 11172176.
  • Santosham, M; Englund, JA; McInnes, P; Croll, J; Thompson, CM; Croll, L; Glezen, WP; Siber, GR (Oct 2001). "Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants". The Pediatric Infectious Disease Journal. 20 (10): 931–40. doi:10.1097/00006454-200110000-00005. PMID 11642626. S2CID 38227210.
  • O'Brien, KL; Moulton, LH; Reid, R; Weatherholtz, R; Oski, J; Brown, L; Kumar, G; Parkinson, A; Hu, D; Hackell, J; Chang, I; Kohberger, R; Siber, G; Santosham, M (Aug 2, 2003). "Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial". Lancet. 362 (9381): 355–61. doi:10.1016/s0140-6736(03)14022-6. PMID 12907008. S2CID 23467115.
  • Klugman, Keith P.; Madhi, Shabir A.; Huebner, Robin E.; Kohberger, Robert; Mbelle, Nontombi; Pierce, Nathaniel (2 October 2003). "A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection". New England Journal of Medicine. 349 (14): 1341–1348. doi:10.1056/NEJMoa035060. PMID 14523142.
  • Dagan, R; Givon-Lavi, N; Fraser, D; Lipsitch, M; Siber, GR; Kohberger, R (Aug 1, 2005). "Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus". The Journal of Infectious Diseases. 192 (3): 367–76. doi:10.1086/431679. PMID 15995949.
  • Santosham, M; Reid, R; Chandran, A; Millar, EV; Watt, JP; Weatherholtz, R; Donaldson, C; Croll, J; Moulton, LH; Thompson, CM; Siber, GR; O'Brien, KL (Mar 22, 2007). "Contributions of Native Americans to the global control of infectious diseases". Vaccine. 25 (13): 2366–74. doi:10.1016/j.vaccine.2006.09.002. PMID 17069936.
  • Siber, GR; Chang, I; Baker, S; Fernsten, P; O'Brien, KL; Santosham, M; Klugman, KP; Madhi, SA; Paradiso, P; Kohberger, R (May 10, 2007). "Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies". Vaccine. 25 (19): 3816–26. doi:10.1016/j.vaccine.2007.01.119. PMID 17368878.
  • de Roux, A; Schmöle-Thoma, B; Siber, GR; Hackell, JG; Kuhnke, A; Ahlers, N; Baker, SA; Razmpour, A; Emini, EA; Fernsten, PD; Gruber, WC; Lockhart, S; Burkhardt, O; Welte, T; Lode, HM (Apr 1, 2008). "Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory". Clinical Infectious Diseases. 46 (7): 1015–23. doi:10.1086/529142. PMID 18444818.
  • Long, D, M. Skoberne, T. M. Gierahn, S. Larson, J. A. Price, V. C, A. E. Baccari, K P. Cohane, D. Garvie, G. R. Siber, and J. B. Flechtner,. Identification of novel virus-specific antigens by CD4+ and CD8+ T cells from asymptomatic HSV-2 seropositive and seronegative donors. Manuscript submitted, Virology 2014.

Books[]

External links[]

Retrieved from ""